TX-SNOW-SOFTWARE
14.12.2022 17:01:37 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today released its latest survey which uncovers how IT decision makers’ priorities have shifted over the past 12 months and their top areas of focus as they head into 2023. The Snow Software 2023 IT Priorities Report polled 800 IT leaders from the United States, United Kingdom, Germany and Australia, and highlights that innovation remains a top priority for organizations (94%). However, reducing costs and managing security risks are competing for leaders’ attention and resources amid continuous market volatility.
Due to economic uncertainty and geopolitical disruptions upending the technology landscape, IT teams have shrinking or stagnant budgets and resources, yet the same goals and KPIs to meet. With increased pressure to foster innovation, boost productivity and remain competitive with fewer resources, IT leaders are struggling to identify where to put their time, energy and spend, resulting in continual strategy pivots.
Responding to Uncertainty in the Market
The report shows that economic uncertainty over the past year has forced nearly all IT leaders to rethink their strategy (80%), with 70% noting immense budget impacts.
When navigating resource reductions and market disruption, IT leaders rely on data and their previous experience to guide decision making. This is particularly true when taking risks and pursuing innovation initiatives, as data is needed to reinforce and rationalize prioritization when resources are limited. While IT leaders feel there is an abundance of data available to them, 89% say IT must invest in tools and technologies to extract value from their data and turn it into actionable intelligence.
Shifting Role of the CIO
Given technology deployments and data insights are often used to provide context through ongoing market volatility, many IT leaders are feeling the weight of their organization’s investments on their shoulders.
The role of the CIO has evolved significantly over the last three years, earning them decision making power not just around technology spend, but across the full scope and impact of the company’s bottom line. With this level of decision making power comes even greater accountability, and the same IT leaders who championed the shift to remote work are also at risk of becoming the scapegoats when businesses are not equipped for unprecedented events. CIOs and other IT leaders are living in an age of adaptation: new technologies, new market dynamics, new value drivers, and they are expected to successfully guide their organizations through a new reality of continual, crisis-fueled change.
“The reality is that IT isn’t going to get a break from the uncertainties impacting businesses anytime soon,” said Alastair Pooley, Chief Information Officer at Snow. “The IT leaders that push through the challenges with confidence all have one thing in common: the ability to access data and leverage it strategically. CIOs should not overlook the power of intelligence on their technology, given it empowers IT teams with data-driven insights to shift their focus from tactical response to strategic initiatives. This shift helps drive continued innovation through extended periods of uncertainty.”
Key Findings Include:
- Competing priorities are stalling IT teams’ ability to forward innovation. While innovation remains a priority for IT leaders, it is stalled as businesses wrestle with reducing cost (33%), managing security risks (28%) and advancing digital transformation (26%) – which leaves IT teams conflicted on where to focus their day-to-day efforts versus long-term strategic views.
- The role of the CIO is continuing to evolve. Over the past 18 months, 78% of respondents reported that the role has evolved immensely over this time. Further, 90% of CIOs say they are trusted advisors to the business, as opposed to a one-stop shop for technology. As expected, the evolution of their role has come with increased responsibilities, such as having more accountability for the financial impact of their IT investments (89%), as well as an expectation to innovate faster and demonstrate ROI (85%). CIOs are tasked with juggling many timely problems and priorities, all while ensuring they are meeting their individual goals and expectations.
- IT leaders are both thriving and drowning in data. The report reveals that 89% of IT leaders have access to actionable data to apply to decision making. However, 60% say they are overwhelmed by data, and 89% say IT must invest in tools and technologies to extract value from their data and turn it into actionable intelligence. A data-led approach is the most reliable way to navigate uncertainty, as it provides leaders with an evidence-based roadmap, as well as arming them with the confidence to make data-driven decisions, even in a rapidly changing environment. CIOs and IT leaders with threadbare teams and budgets will be challenged to do it all and need to rely on easily accessible data to drive optimal business decisions. In 2023, approaches like Technology Intelligence – or the ability to understand and manage all technology – will be the catalyst to continued success.
For more information about the latest version of the Snow annual report, please visit: https://www.snowsoftware.com/go/it-priorities/
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
